Your session is about to expire
← Back to Search
Other
Drug for Diabetic Neuropathy
Phase 2
Waitlist Available
Research Sponsored by XTL Biopharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 weeks
Awards & highlights
Study Summary
To compare the efficacy of two dosages (600mg/day and 1200mg/day) of bicifadine SR with placebo for 14 weeks in reduction of chronic neuropathic patin (measured by a daily rating of pain intensity) associated with diabetic periperal neuropathy in adult outpatients. To compare the tolerability of two dosages of bicifadine SR with placebo in adult outpaitens treated for chronic neuropathic pain for 14 weeks associated with diabetic peripheral neuropathy.
Eligible Conditions
- Diabetic Neuropathy
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 14 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Pain and Safety
Secondary outcome measures
Clinical Global Impression of Improvement, McGill Pain Questionnaire, Amount of Rescue Medication Used for Pain, Quality of Life Survey (SF-36), Patient Global Impression of Change
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Drug: 2Experimental Treatment1 Intervention
Bicifadine
Group II: DrugExperimental Treatment1 Intervention
Bicifadine
Group III: ControlPlacebo Group1 Intervention
Placebo of Bicifadine
Find a Location
Who is running the clinical trial?
XTL BiopharmaceuticalsLead Sponsor
3 Previous Clinical Trials
346 Total Patients Enrolled
Mark Roffman, PhDStudy DirectorXTL Bio
1 Previous Clinical Trials
250 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger